Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 8:56 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Blue Owl Capital Holdings LP | 1,493,252 5.74% | 1,493,252 (New Position) | View |
| 2024-02-13 8:22 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Avidity Partners Management LP | 2,662,206 9.9% | 472,487 (+21.58%) | View |
| 2024-02-13 7:02 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Ally Bridge MedAlpha Master Fund L.P. | 570,976 2.6% | -868,403 (-60.33%) | View |
| 2024-02-13 6:59 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Bain Capital Life Sciences Fund II L.P. | 2,749,808 11% | 625,114 (+29.42%) | View |
| 2024-02-09 5:08 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Artal International S.C.A. | 3,568,842 9.9% | 2,105,013 (+143.80%) | View |
| 2024-02-07 07:09 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,623,984 9.99% | 1,370,156 (+109.28%) | View |
| 2024-01-02 4:15 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Point72 Asset Management L.P. | 1,471,771 5.7% | 1,471,771 (New Position) | View |
| 2023-12-26 5:19 pm Purchase | 13D | SYROS PHARMACEUTICALS INC SYRS | Samsara BioCapital L.P. | 2,515,523 9.5% | 909,977 (+56.68%) | View |
| 2023-10-20 4:15 pm Purchase | 13D | SYROS PHARMACEUTICALS INC SYRS | Samsara BioCapital L.P. | 1,605,546 7.5% | 1,605,546 (New Position) | View |
| 2023-02-14 4:07 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Avidity Partners Management LP | 2,189,719 9.9% | 69,719 (+3.29%) | View |
| 2023-02-14 06:15 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Bain Capital Life Sciences Fund II L.P. | 2,124,694 11% | 2,124,694 (New Position) | View |
| 2023-02-10 7:41 pm Sale | 13G | SYROS PHARMACEUTICALS INC SYRS | Artal International S.C.A. | 1,463,829 7.2% | -2,036,171 (-58.18%) | View |
| 2023-01-27 6:01 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.9% | 1,439,379 (New Position) | View |
| 2023-01-25 5:00 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | ADAGE CAPITAL PARTNERS GP L.L.C. | 1,253,828 6.04% | 1,253,828 (New Position) | View |
| 2022-11-10 11:55 am Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | FMR LLC | 104,614 0.516% | 104,614 (New Position) | View |
| 2022-09-20 4:35 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Avidity Partners Management LP | 2,120,000 9.9% | 2,120,000 (New Position) | View |
| 2022-09-19 4:07 pm Purchase | 13G | SYROS PHARMACEUTICALS INC SYRS | Deep Track Capital LP | 699,281 9.99% | 699,281 (New Position) | View |
| 2022-09-16 4:31 pm Sale | 13D | SYROS PHARMACEUTICALS INC SYRS | TYME TECHNOLOGIES INC. TYME | 0 0% | -17,460,552 (Position Closed) | View |
| 2022-07-13 5:15 pm Purchase | 13D | SYROS PHARMACEUTICALS INC SYRS | TYME TECHNOLOGIES INC. TYME | 17,460,552 28% | 17,460,552 (New Position) | View |
| 2022-07-13 5:10 pm Purchase | 13D | TYME TECHNOLOGIES, INC. CO TYME | Syros Pharmaceuticals Inc. SYRS | 17,819,723 9.9% | 17,819,723 (New Position) | View |